ArticleNature communications2023
Pre-activated nanoparticles with persistent luminescence for deep tumor photodynamic therapy in gallbladder cancer.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 86 citations in OpenAlex.
- Ambient Light-Activatable Luminescent Particle-Embedded Conformal Patch for Photochemical Tissue Bonding and Photobiomodulated Healing.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Tumor acid-triggered sericin prodrug colloidal system for enhanced photodynamic and ferroptosis therapy of breast cancer.Materials today. Bio · 2026Article
- Endogenous near-infrared chemiluminescent manganese ion-driven porphyrin supramolecular platform for the theranostics of thrombosis and ischemic stroke.RSC advances · 2026Article
- Long-Acting Dynamic Therapy Using X-Ray Activated Organic Nanoparticles for Afterglow Imaging Guided Deep Tumor Treatment.Angewandte Chemie (International ed. in English) · 2026Article
- Tunable persistent luminescence nanoparticles for profiling bacterial extracellular azoreductase activity and antibiotic susceptibility.Analytical and bioanalytical chemistry · 2026Article
- D-peptide engineered hydrogel with dual-enzyme-ALA cascades enables multimodal oxygen modulation for self-sustaining EDT-PDT synergy.Bioactive materials · 2026Article
- X-ray preactivated reversible persistent luminescence enables photodynamic immunotherapy of deep tumors.Nature communications · 2026Article
- Engineering combination nanomedicines to overcome cancer resistance.RSC advances · 2026Review
- Illumination of Targeting Nanotherapeutics with Precision Eyes: From Optical to Radio-nanotheranostics.Theranostics · 2026Review
- Research trends and hotspots of upconversion nanoparticles for drug delivery and biomedical targeting in photodynamic therapy.Discover nano · 2025Review
- Molecular afterglow imaging for biomedical applications.Nature materials · 2025Review
- A long-term self-driven metronomic photodynamic system for cancer therapy.Nature communications · 2025Article
- Sonodynamic and Bioorthogonal Sonocatalytic Thrombotic Therapy Based on AIE Cationic Tetranuclear Ir(III) Complex Nanoplatform Guided by NIR-Chemiluminescence Imaging.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Strategies to enhance the effects of nanotechnology-mediated photodynamic therapy.Nanomedicine (London, England) · 2025Review
- Challenges and opportunities in next-generation LED therapeutic devices.Light, science & applications · 2025Review
- Targeted Intracellular Copper Reservoir Enhances Liver Cancer Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Adjuvant chemotherapy for gallbladder cancer: Current evidence, controversies, and future directions.World journal of gastrointestinal surgery · 2025Article
- Organic Afterglow Materials for Tumor Diagnosis and Therapy.Biosensors · 2025Review
- Establishment and characterization of a new human gallbladder cancer cell line, OCUG-2.World journal of experimental medicine · 2025Article
- A dark-state-dominated photochemical upconversion afterglow via triplet energy transfer relay.Science advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phototherapy of deep tumors still suffers from many obstacles, such as limited near-infrared (NIR) tissue penetration depth and low accumulation efficiency within the target sites. Herein, stimuli-sensitive tumor-targeted photodynamic nanoparticles (STPNs) with persistent luminescence for the treatment of deep tumors are reported. Purpurin 18 (Pu18), a porphyrin derivative, is utilized as a photosensitizer to produce persistent luminescence in STPNs, while lanthanide-doped upconversion nanoparticles (UCNPs) exhibit bioimaging properties and possess high photostability that can enhance photosensitizer efficacy. STPNs are initially stimulated by NIR irradiation before intravenous administration and accumulate at the tumor site to enter the cells through the HER2 receptor. Due to Pu18 afterglow luminescence properties, STPNs can continuously generate ROS to inhibit NFκB nuclear translocation, leading to tumor cell apoptosis. Moreover, STPNs can be used for diagnostic purposes through MRI and intraoperative NIR navigation. STPNs exceptional antitumor properties combined the advantages of UCNPs and persistent luminescence, representing a promising phototherapeutic strategy for deep tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.